New ‘concerning’ data find that most US endoscopists aren’t following current polypectomy guidelines for polyps < 1 cm, ...

While colorectal cancer polyps often have no symptoms—especially in the early stages—there are some warning signs to be on ...

The FDA has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with ...

Personalized dosing strategies may be necessary for biologic therapies, especially fixed-dose options like ustekinumab, due ...

Viraaj is a spirited gamer, lifelong PlayStation main, huge petrolhead, but most importantly, a principled journalist. With experience at publications like FandomWire, HotCars, and DriveTribe, writing ...

It's quick and easy to access Live Science Plus, simply enter your email below. We'll send you a confirmation and sign you up for our daily newsletter, keeping you up to date with the latest science ...

Lipopolyplexes are emerging as effective, second-generation, nonviral vectors to deliver gene therapies, yet there are challenges. To resolve them, researchers at the University of Milan have ...

1] Advance Agrolife IPO GMP today: According to market observers, shares of Advance Agrolife Limited are available at a premium of ₹5 in the grey market today. 2] Advance Agrolife IPO size: The ...

Astronomers are tracking a newly discovered interstellar visitor called 3I/ATLAS, and early research suggests it may be unusually massive. The comet was first spotted on July 1, 2025, by the ATLAS ...

AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Amgen Inc. (NASDAQ:AMGN) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 22, Amgen Inc.’s (NASDAQ:AMGN) and AstraZeneca’s Tezspire received a positive ...

Amgen (AMGN) and AstraZeneca (AZN) are approaching a potential catalyst event on October 19, when the FDA will rule on Tezspire for treating chronic rhinosinusitis with nasal polyps (CRSwNP). If ...